Highlights

  • Wall Street Zen raised its rating on Arcutis Biotherapeutics recently.
  • Brokerage firms issued mixed rating and target adjustments over recent months.
  • Analyst consensus currently reflects a Moderate Buy classification.

Wall Street Zen recently updated its assessment of Arcutis Biotherapeutics Inc. (NASDAQ:ARQT), upgrading the stock from a buy rating to a strong-buy rating in a report released on Sunday. The change followed a series of analyst updates tied to earnings performance and broader sector developments.

Other research firms have also adjusted their views on the company. Goldman Sachs raised its price target from USD 19.00 to USD 29.00 while maintaining a neutral rating. HC Wainwright reiterated a buy rating and issued a USD 30.00 target, while Needham & Company increased its target from USD 22.00 to USD 30.00 with a buy designation. Mizuho raised its price objective from USD 32.00 to USD 37.00 and assigned an outperform rating. Conversely, Zacks Research lowered its rating from strong-buy to hold in a late-December note.

Based on aggregated analyst data, six analysts have issued buy ratings, two have assigned hold ratings, and one has issued a sell rating. Collectively, these assessments result in a consensus rating described as Moderate Buy, with an average price target of USD 29.00.

Arcutis Biotherapeutics reported quarterly earnings on October 28, posting USD 0.06 earnings per share, compared with expectations for a loss. Quarterly revenue totaled approximately USD 99.22 million, exceeding consensus estimates. The company reported a negative net margin of 13.94% and a negative return on equity of 29.69%. Analysts anticipate a full-year loss of approximately USD 1.33 per share.

Recent disclosures also showed insider share sales during the past three months, while institutional investors adjusted holdings through a mix of position increases and new entries.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for immuno-inflammatory skin conditions using targeted, topical treatment approaches.

ARQT closed at USD 29.00 on January 02, 2026.